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Abstract The effect of peptides homologous to segments of a 
G protein-coupled receptor on the GTPase activity of recombi- 
nant Goa (rGoa) and G~a (rG~a) has been tested. These peptides 
contain overlapping sequences panning from amino acid 212 of 
the putative fifth transmembrane domain to amino acid 229 of the 
third cytoplasmic loop of the oz2 adrenergic receptor. Interest- 
ingly, two peptides (comprising residues 212-227 and 214-227) 
strongly inhibit the basal GTPase activity of both rGo~ and rG~. 
Instead, a C-terminally extended peptide (residues 216-229) 
stimulates rGo~ but slightly inhibits rG~a. Circular dichroism 
spectroscopy of the peptides reveals that an a helical structure is 
more easily inducible in the inhibitory ones. These findings consti- 
tute an example of peptides representing cytoplasmic receptor 
sequences that differentially modulate the GTPase activity of 
recombinant G protein a-subunits. 
Key words: Receptorial peptide; CD spectroscopy; G protein 
c~-subunit; GTPase activity 
1. Introduction 
Cell surface receptors with seven transmembrane domains 
transduce signals to ion channels or to intracellular effectors 
(enzymes involved in the synthesis of second messengers such 
as cyclic nucleotides, phosphoinositols and diacylglycerols) 
through eterotrimeric (consisting of ~, fl and 7/subunits) gua- 
nine nucleotide binding proteins (G proteins). Upon receptor- 
ligand interaction, GDP is exchanged for GTP on the G pro- 
tein's ~-subunit, which subsequently dissociates from the recep- 
tor and the fl), dimer and modulates the activity of ion channels 
or effectors. Following GTP hydrolysis, GceGDP reassociates 
with fly on the inner surface of the cell membrane [14]. 
There is convincing evidence that the receptors regulate G 
proteins through their intracellular loops. It has been shown for 
several receptors that one of these regions corresponds to the 
N-terminal segment of the third cytoplasmic loop [5]. However, 
in the case of the ~2A-adrenergic receptor it is at present unclear 
whether or not this receptor's respective segment participates 
in the interaction with G proteins. Switching the sequence in 
this region of the fl2-adrenergic receptor to that of the c~ 2- 
adrenergic receptor does not change the specificity of interac- 
tion with the G protein. Such mutants of the fl2-adrenergic 
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receptor still couple to G~ as judged by the agonist induced 
stimulation of adenylate cyclase activity [6-8]. It has also been 
reported that a dodecapeptide homologous to the N-terminal 
portion of the third intracellular loop of the ~2-adrenergic re-
ceptor (residues 218-229) does not interfere with the activation 
of G proteins. In the presence of ligand, receptor-stimulated 
GTP hydrolysis in platelet membranes i  unaffected by the 
peptide [9]. On the other hand, it has been shown that an 
analogous undecapeptide, differing only by the lack of the 
C-terminal amino acid, markedly stimulates GTP?'S binding to 
purified G i, G~,, and Gs [10]. 
We have attempted to further elucidate the possible role of 
the c~2-adrenergic receptor's N-terminal segment of its third 
intracellular region in coupling to G proteins. To this end we 
have tested the effect of peptides, derived from that segment 
and part of the adjacent fifth transmembrane domain, on the 
basal GTPase activity of recombinant ~ subunits of G O and G~ 
(rGo~t and rG~:z). The peptides have a common core sequence 
with different C- or N-terminal extensions that include amino 
acid residues 218-229 of the receptor. Depending on the exten- 
sion, we observe different effects (stimulation or inhibition) on 
the GTPase activity of rGoc~. The GTP hydrolysis by rGsc~, 
instead, is not affected by one of these peptides and is inhibited 
by the others. 
2. Experimental 
2.1. Recombinant Got subunits 
The E. coli strain BL21(DE3) harboring the GoC~ expression vector 
NpT7-5/Go~ was provided by Dr. Maurine Linder (University of Texas 
Southwestern Medical Center, Dallas, Texas). Cell growth and induc- 
tion of protein expression were obtained as described [11]. The expres- 
sion of recombinant Go~ was verified by SDS/PAGE of induced lysates 
on 12.5% slab gels according to Laemmli [12] after Coomassie blue 
staining, as well as after immunoblot analysis using a 1 : 10,000 dilution 
of a rabbit antiserum specific for Go0~ [13], provided by Dr. Graeme 
Milligan (University of Glasgow, Scotland). The purification of the 
recombinant G,,ot from bacterial lysates was carried out as previously 
reported [14]. The recombinant G~ot subunit (G~c~-s, 45 kDa form), 
purified according to a slightly modified protocol [15], was a gift from 
Drs. Christian Nanoff and Michael Freissmuth (University of Vienna, 
Austria). Overall protein concentrations were determined by the 
method of Bradford [16], whereas the concentrations of active G pro- 
tein ot subunits were determined by [y-35S]GTP binding [17]. 
2.2. GTP hydrolysis 
Reconstitution f rGoot into phospholipid vesicles and determination 
of GTP hydrolysis by this protein in the absence or in the presence of
peptides, were performed as previously described [14]. Alternatively, 
rGoct or rG~ot were incubated for 5 min at 20°C or 30°C respectively, 
in 50 ~1 of a reaction mixture containing 50 mM HEPES-KOH (pH 8), 
lmM EDTA, 1 mM DTT and 0.1% Lubrol (HEDLI and in the case 
of rG,,ot, 1.1 mM MgCI: and 0.4/,tM [T-32p]GTP: while in the case of 
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rG~, 2 mM MgCI2 and 1/tM [T-32p]GTP (10,000-30,000 cpm/pmol). 
Each experiment was repeated at least twice and each point shown 
represents he average of duplicate determinations. 
2.3. Peptides 
Peptides l and 4 were synthesized on an ABIMED AMS 422 multiple 
peptide synthesizer using fluorenylmethoxycarbonyl (Fmoc) chemistry 
[18] for the coupling reactions. Instead, in the synthesis of peptides 2
and 3, tertiary butyloxycarbonyl (tboc) chemistry was employed using 
the method eveloped by Houghten [19]. The peptides (about 5 mg each 
of the raw product) were purified by HPLC on a Merck LiChrospher 
300 RP 18 column (10 × 250 mm) applying varying linear gradients 
of acetonitrile (typically 20-30% in 40 rain) in 0.1% trifluoroacetic acid 
at a flow rate of 2 ml/min. The purified peptides were concentrated to 
dryness in a Speedvac oncentrator, redissolved in 0.2 ml of bidestilled 
water, concentrated to dryness again and finally dissolved in 0.1 ml of 
bidestilled water. Their purity was assessed by analytical RP-HPLC and 
their concentrations were determined as described [20] 
2.4. Circular dichroism spectroscopy 
CD spectra were measured at room temperature in a 1 mm cell (total 
volume 1.1 ml) using a JASCO 600 spectropolarimeter. The final con- 
centration of the peptides was 50 tiM. Trifluoroethanol r lyso- 
phosphatidylcholine w re added as indicated. Each spectrum is the 
average of five scans at 10 nm/min. 
3. Resu l ts  
3.1. Effects of receptorial peptides on the GTPase activity of 
rGoct 
Four peptides corresponding to sequences panning from 
residue 212 to residue 229 of the human cz2A-adrenergic recep- 
tor were synthesized and purified by RP-HPLC. These peptides 
comprised overlapping sequences of the N-terminal region of 
the third cytoplasmic loop and part of the adjacent fifth trans- 
membrane domain (Table 1). Their effect on the basal GTPase 
activity of rGo~ was first determined with protein that had been 
reconstituted into phospholipid vesicles (Fig. 1). Under these 
conditions, peptide 1 (amino acids 218-228) and peptide 3 
(amino acids 216-229) stimulated the GTP hydrolysis by rGo~ 
in a concentration-dependent manner (Fig. 1A), the former 
enhancing the activity nearly 1.5-fold and the latter 2-fold at 
1 mM peptide. Instead, peptide 4 (amino acids 212-227) and 
peptide 2 (amino acids 214~227) strongly inhibited the basal 
GTPase activity of rGJz (Fig. 1B). In the case of peptide 4 the 
inhibition was virtually complete, reaching over 90% at a con- 
centration of 320/IM. Peptide 2 was less potent, with 80% 
inhibition at 1 mM peptide. 
3.2. Inhibition of the GTPase activity of rGsOt by receptorial 
peptides 
The effect of the same four peptides (see above and Table 1) 
Table 1 
Synthesized peptides 
Peptide Sequence Residue 
numbers 
R-I-Y-Q-I-A-K-R-R-T-R 218-228 
L-V-Y-V-R-I-Y-Q-I-A-K-R-R-T 21~227 
Y -V-R- I -Y -Q- I -A -K -R-R-T -R-V  21~229 
M- I -L -V -Y -V -R- I -Y -Q- I -A -K -R-R-T  212-227 
These peptides represent sequences present in the mammalian ~2A- 
adrenergic receptor. The underlined amino acid residues are part of the 
putative 5th transmembrane domain, the others constitute he N-termi- 
nal segment of the third cytoplasmic loop. 
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Fig. 1. Opposite ffects on the GTPase activity of rGo~ reconstituted 
into phospholipid vesicles. The rGo~ was preincubated in a mixture of 
phospholipids at4°C overnight and subsequently he GTP hydrolysis 
was assayed at 20°C for 5 minutes in a final volume of 50/A in the 
presence of peptide 3 (o) or peptide 1 (m) (panel A) and peptide 2 (e) 
or peptide 4 (A) (panel B). Under these conditions, 100% GTPase 
activity corresponds to a molar turnover number of 0.028 min -~. The 
final protein concentration was 60 nM as determined by [7-35S]GTP 
binding. The data represent the mean of duplicate measurements of 
three separate xperiments, 
on the basal GTPase activity of rGs~ was measured in the 
presence of a detergent ( 0.1% Lubrol) according to Graziano 
et al. [21]. While peptide 1 had no effect (up to a concentration 
of 1 mM), peptides 2, 3 and 4 inhibited the GTP hydrolysis by 
this protein to varying extents and with different potencies (Fig. 
2). The inhibition by peptide 2 leveled off at a concentration of
560/tM but having reached only about 50%. Similarly, at the 
same concentration peptide 3 decreased the basal GTPase ac- 
tivity of rGscZ by a maximum 60%. However, as opposed to 
peptide 2, peptide 3 started to have an effect only above 200 
/.tM. In the presence of peptide 4, the GTP hydrolysis was 
already inhibited by more than 75% at 10 gtM and was abol- 
ished at 100/.tM peptide. 
3.3. Inhibition of the GTPase activity of rGit and rGoct by 
peptide 4 
For the purpose of assessing the actual potency of the inhib- 
itory peptide 4, it was also tested at concentrations below 
10/~M (Fig. 3). The GTPase activity of rGs~ declined sharply 
in the rather narrow concentration range of 3-10 ~tM peptide. 
When the GTP hydrolysis by rGjz  was assayed under similar 
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Fig. 2. Inhibition of the basal GTPase activity of rGscz. The rGs~z was 
incubated in the presence of 0.1% Lubrol, at a final protein concentra- 
tion of 40 nM, as described in the experimental section. 100% GTPase 
activity corresponds toa molar turnover number of 0.095 min -~. Pep- 
tide 1 (u), peptide 2 (e), peptide 3 (o) and peptide 4 (A). 
conditions (i.e. in the presence of 0.1% Lubrol) the inhibitory 
effect of peptide 4 was less pronounced than with rGscZ (Fig. 3). 
However, the concentration of peptide 4 needed to inhibit the 
GTPase activity of rGocZ by 90% or more was much lower (100 
aM) in the presence of Lubrol than in the case where the 
protein had been reconstituted into phospholipid vesicles (320 
/IM, compare Fig. 1). 
3.4. Circular dichroism spectroscopy of receptorial peptides 
In order to obtain information about possible structures 
adopted in solution, the four peptides were analysed by CD 
spectroscopy in the 190-240 nm range. In aqueous olution, in 
the absence or presence of a detergent (0.1% Lubrol), these 
peptides do not form ordered secondary structures (data not 
shown). Structural transitions can be induced by gradually in- 
creasing the concentration of trifluoroethanol, solvent used to 
create a hydrophobic environment. For example, in the spectra 
obtained with peptides 2 and 3 (Fig. 4) the addition of 
trifluoroethanol causes the negative Uipticity to shift towards 
longer wavelengths, which is characteristic for an increasing 
content of cz-helical structure. The shift occurs at a relatively 
low concentration of trifluoroethanol (20%) in the case of pep- 
tide 2, whereas peptide 3 starts to adopt cz-helical structure 
above 40% of the solvent (Fig. 4). In the presence of the same 
increasing percentages of trifluoroethanol, peptide 4 behaves 
exactly like peptide 2 (spectra not shown). The spectra obtained 
with peptide 1 do not change as the percentage of trifluoroetha- 
nol in the solution is increased, indicating that it remains in the 
random coil form. These results reveal the propensity of the 
peptides with elongated N-termini (which include a part of the 
putative transmembrane domain) to form ordered structures. 
The same structural transitions can also be observed with pep- 
tides 4 and 2 in the presence of lysophosphatidylcholine, a 
phospholipid used to emulate a membrane nvironment (Fig. 
5). As judged by the spectra obtained under these conditions, 
peptide 3 is much less structured as compared to the former 
two, while peptide 1 is a random coil also in the presence of the 
phospholipid. 
4. Discussion 
Cell surface receptors featuring seven transmembrane do- 
mains interact with G proteins through portions of their intra- 
cellular loops [4,5]. A segment of the third cytoplasmic loop 
(comprising the N-terminal 11 amino acids) of the mammalian 
~2A-adrenergic receptor has been implicated in the activation 
of G proteins [10]. We have further investigated the involve- 
ment in G protein coupling of the N-terminal region of this 
receptor's third cytoplasmic loop using corresponding synthetic 
peptides that also contain some amino acids of the adjacent 
fifth transmembrane domain. The four peptides, panning from 
residue 212 in the fifth transmembrane domain to residue 229 
in the third intracellular loop, have a common core sequence 
of 10 amino acids and varying C- or N-terminal extensions 
(Table 1). 
In current models of signal transduction the interaction be- 
tween agonist-bound receptors and G proteins induces the ex- 
change of GDP for GTP on the G protein c~-subunit, leading 
to effector activation and ultimately to an enhancement of the 
intrinsic GTPase activity of the cz-subunit [1~4]. However, it 
was recently shown that the activated prostaglandin E receptor 
EP3c couples to two different G proteins, G~ and G o, but differ- 
entially regulates them, stimulating the GTPase activity of Gs 
and inhibiting that of Go [22]. Evidence indicating receptor- 
mediated inhibition of the GTP hydrolysis by Gil and Gi2 but 
not G O , was also found with reconstituted membranes from 
guinea pig cerebellum in the presence of an opiod tc-agonist 
[231. 
Here we have shown that synthetic peptides, representing 
overlapping sequences of the cz2A-adrenergic receptor's N-ter- 
minal segment of the third cytoplasmic loop and part of the 
adjacent fifth transmembrane domain, inhibit the GTP hydrol- 
ysis by rGo~Z and rGsc~. Peptide 4, which contains 16 amino 
acids, is the most potent inhibitor of both GTPase activities. 
Among the two tetradecapeptides 2 and 3, peptide 2 inhibits the 
GTP hydrolysis by both proteins, while peptide 3 exerts its 
inhibitory effect only on rG~c~. These results further suggest that 
receptors can negatively regulate G protein activity. 
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Fig. 3. Inhibition of the basal GTPase activity of rGjz and rGs0~ by 
peptide 4. The GTP hydrolysis by rGo~Z or rGsCC was determined as 
described in the legend to Fig. 2, but in the presence of lower concentra- 
tions of peptide 4. Under these conditions, 100% GTPase activities 
correspond tomolar turnover numbers for rGocZ and for rG,cz of 0.099 
and of 0.095 min -~' respectively. The final protein concentrations were 
60 nM for rGocZ (I) and 40 nM for rGscz (o). 
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Peptide l already has been shown to stimulate GTPy S bind- 
ing to heterotrimeric G,  G O and G~ [10]. This peptide and 
peptide 3 stimulate the GTPase activity of rGoa, while peptides 
2 and 4 are inhibitory. Peptide 3 is 'frame shifted' by two amino 
acids as compared to peptide 2, whereas peptide 1 is a truncated 
version of peptide 3 (see Table 1). It is remarkable that such 
subtle differences give rise to opposite ffects on the enzymatic 
activity of rGoa. This suggests that the molecular mechanism 
of G protein regulation may involve only a few critical amino 
acids of the receptor. 
Recently it has been reported that only a few charged amino 
acids at the membrane/cytoplasm boundary of the m3 muscar- 
inic acetylcholine r ceptor's third intracellular loop appear to 
be important for signal transduction [24]. In this context it is 
noteworthy that an arginine residue is present at the extended 
C-terminus of both stimulatory peptides, but is absent in the 
inhibitory ones. This arginine, which corresponds to residue 
228 of the a2-adrenergic receptor, may thus be relevant for the 
receptor's ability to activate Go~. 
The N-termini of peptides 3, 2 and 4 comprise, respectively, 
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Fig. 4. CD spectra of peptides 2and 3 in the presence of trifluoroetha- 
nol. The spectra were recorded as described in the experimental section 
for peptides 2(panel A) and 3 (panel B) in aqueous olutions containing 
10% ( . . . .  ), 20% ( ), 30% ( -) or 40% (-----) trifluoroethanol. 
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Fig. 5. CD spectra of peptides in the presence of phospholipid. The 
aqueous olutions of peptides 1 ( . . . .  ), 2 ('""), 3 ( - -  -) and 4 (- -  ) 
contained L-~-lysophosphatidyl choline at 1 mg/ml. 
two, four and six residues from the receptor's fifth transmem- 
brane domain in addition to the contiguous intracellular seg- 
ment of the third cytoplasmic loop represented by peptide 1. 
As the length of this hydrophobic tail increases, the peptides 
become more potent inhibitors of the GTPase activities (in the 
case of rGoa this applies only to peptides 2 and 4). The peptides 
with hydrophobic tails indeed have a propensity to become 
partly c~-helical, but only in a lipidic environment as shown by 
CD spectroscopic analysis. It is therefore likely that the hydro- 
phobic residues interact directly with the G protein a-subunits 
rather than inducing structural conformations that facilitate 
their mode of action. The varying effects that a receptor may 
exert on the same G protein a-subunit could reflect different 
extents of hydrophobic amino acid exposure in the receptor's 
G protein-coupling sites. 
It has been proposed that the intracellular regions of recep- 
tors interacting with G proteins possess amphiphilic a-helical 
properties [25,26]. Contrary to this model, Voss et al. reported 
that a peptide derived from the third cytoplasmic loop's N- 
terminal portion of the dopamine D2 receptor specifically inter- 
fered with signal transduction by this receptor, but did not form 
an amphiphilic a-helix [27]. CD spectroscopy of the peptides 
studied here revealed that peptides 2, 3 and 4 could adopt 
partial a-helical structures in a phospholipidic environment, 
where their differential effects on the activity of rGoa are most 
pronounced. However, peptide 4 is a much more potent inhib- 
itor of the GTPase activities of both G protein a-subunits in 
the presence of detergent, where this peptide is not structured 
at all as judged by spectroscopic analysis. In addition, none of 
the four peptides is amphiphilic. Therefore, our observations 
add further doubt to the concept of an amphiphilic a-helix as 
the G protein interacting entity in receptors featuring seven 
transmembrane domains. 
In conclusion, here we have reported studies on peptides 
homologous to sequences of a cell surface receptor with seven 
transmembrane domains that negatively modulate the activity 
of recombinant G protein a subunits. Furthermore, we have 
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provided evidence suggesting that the ~2A-adrenergic receptor 
can oppositely regulate the GTPase activity of Go~ and that 
such opposite ffects can be the result of a shifted exposure of 
a few amino acids at the boundary of the receptor's fifth trans- 
membrane domain and its third cytoplasmic loop. 
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